Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 11
HOS-124250 · Präparat HOS-095825
The following are all adverse reactions that were reported with paliperidone by frequency category
estimated from paliperidone palmitate clinical trials. The following terms and frequencies are applied:
very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare
(≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); and not known (cannot be estimated from the
available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage be6218d542caf8be69203b2b2d772e53c776284fb514f2d86f43a44d1535f229 · Zeichen 520–926 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 11
HOS-124251 · Präparat HOS-095825
System Organ Adverse reactions
Class Frequency
Very Common Uncommon Rare Not knowna
common
Infections and upper respiratory pneumonia, bronchitis, eye infection,
infestations tract infection, respiratory tract acarodermatitis
urinary tract infection, sinusitis,
infection, influenza cystitis, ear infection,
tonsillitis,
onychomycosis,
cellulitis,
subcutaneous abscess
Blood and white blood cell count neutropenia, agranulocytosis
lymphatic system decreased, anaemia thrombocytopenia,
disorders eosinophil count
increased
Immune system hypersensitivity anaphylactic
disorders reaction
Endocrine hyperprolactinaemiab inappropriate
disorders antidiuretic
hormone
secretion, glucose
urine present
Metabolism and hyperglycaemia, diabetes mellitusd, diabetic water intoxication
nutrition weight increased, hyperinsulinaemia, ketoacidosis,
disorders weight decreased, increased appetite, hypoglycaemia,
decreased appetite anorexia, blood polydipsia
triglycerides increased,
blood cholesterol
increased
Psychiatric insomniae agitation, depression, sleep disorder, mania, catatonia, sleep-related
disorders anxiety libido decreased, confusional state, eating disorder
nervousness, somnambulism,
nightmare blunted affect,
anorgasmia
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 0b25a5c01d9d7fdba185853be330632ca0beddae58c6b7bb55e5bfa0eae94e85 · Zeichen 930–4153 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 11–12
HOS-124252 · Präparat HOS-095825
11
Nervous system parkinsonismc, tardive dyskinesia, neuroleptic diabetic coma
disorders akathisiac, syncope, psychomotor malignant
sedation/somnolence, hyperactivity, syndrome,
dystoniac, dizziness, dizziness postural, cerebral
dyskinesiac, tremor, disturbance in ischaemia,
headache attention, dysarthria, unresponsive to
dysgeusia, stimuli, loss of
hypoaesthesia, consciousness,
paraesthesia depressed level of
consciousness,
convulsione,
balance disorder,
coordination
abnormal, head
titubation
Eye disorders vision blurred, glaucoma, eye floppy iris
conjunctivitis, dry eye movement syndrome
disorder, eye (intraoperative)
rolling,
photophobia,
lacrimation
increased, ocular
hyperaemia
Ear and labyrinth vertigo, tinnitus, ear
disorders pain
Cardiac disorders tachycardia atrioventricular block, atrial fibrillation,
conduction disorder, sinus arrhythmia
electrocardiogram QT
prolonged, postural
orthostatic tachycardia
syndrome,
bradycardia,
electrocardiogram
abnormal, palpitations
Vascular hypertension hypotension, pulmonary ischaemia
disorders orthostatic hypotension embolism, venous
thrombosis,
flushing
Respiratory, cough, nasal dyspnoea, sleep apnoea hyperventilation,
thoracic and congestion pharyngolaryngeal syndrome, pneumonia
mediastinal pain, epistaxis pulmonary aspiration,
disorders congestion, dysphonia
respiratory tract
congestion, rales,
wheezing
Gastrointestinal abdominal pain, abdominal discomfort, pancreatitis, ileus
disorders vomiting, nausea, gastroenteritis, intestinal
constipation, dysphagia, dry mouth, obstruction,
diarrhoea, dyspepsia, flatulence swollen tongue,
toothache faecal
incontinence,
faecaloma,
cheilitis
Hepatobiliary transaminases gamma- jaundice
disorders increased glutamyltransferase
increased, hepatic
enzyme increased
Skin and urticaria, pruritus, rash, drug eruption, Stevens-Johnson
subcutaneous alopecia, eczema, dry hyperkeratosis, syndrome/toxic
tissue disorders skin, erythema, acne seborrhoeic epidermal
dermatitis, necrolysis,
dandruff angioedema, skin
discolouration
Musculoskeletal musculoskeletal pain, blood creatine rhabdomyolysis, posture abnormal
and connective back pain, arthralgia phosphokinase joint swelling
tissue disorders increased, muscle
spasms, joint stiffness,
muscular weakness
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 1defe6b81dd55d890d3fe8f9158a688bd555858ce1806b927c4de1fbf365ed48 · Zeichen 4214–10137 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 12–13
HOS-124253 · Präparat HOS-095825
12
Renal and urinary incontinence, urinary retention
urinary disorders pollakiuria, dysuria
Pregnancy, drug withdrawal
puerperium and syndrome
perinatal neonatal (see
conditions section 4.6)
Reproductive amenorrhoea erectile dysfunction, priapism, breast
system and breast ejaculation disorder, discomfort, breast
disorders menstrual disordere, engorgement,
gynaecomastia, breast
galactorrhoea, sexual enlargement,
dysfunction, breast vaginal discharge
pain
General disorders pyrexia, asthenia, face oedema, oedemae, hypothermia, body temperature
and fatigue, injection site body temperature chills, thirst, drug decreased,
administration reaction increased, gait withdrawal injection site
site conditions abnormal, chest pain, syndrome, necrosis,
chest discomfort, injection site injection site
malaise, induration abscess, injection ulcer
site cellulitis,
injection site cyst,
injection site
haematoma
Injury, poisoning fall
and procedural
complications
a
The frequency of adverse reactions is qualified as “not known” because they were not observed in paliperidone palmitate
clinical trials. They were either derived from spontaneous post-marketing reports and frequency cannot be determined, or they
were derived from risperidone (any formulation) or oral paliperidone clinical trials data and/or post-marketing reports.
b
Refer to ‘Hyperprolactinaemia’ below.
c
Refer to ‘Extrapyramidal symptoms’ below.
d
In placebo-controlled trials, diabetes mellitus was reported in 0.32% in Xeplion-treated subjects compared to a rate of 0.39%
in placebo group. Overall incidence from all clinical trials was 0.65% in all Xeplion treated subjects.
e
Insomnia includes: initial insomnia, middle insomnia; Convulsion includes: grand mal convulsion; Oedema includes:
generalised oedema, oedema peripheral, pitting oedema. Menstrual disorder includes: menstruation delayed, menstruation
irregular, oligomenorrhoea.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 581f9f2d30efe37258892f7a6afbdd0220bd4575f578fb302228eeb4ffe5c32c · Zeichen 10185–13855 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-124254 · Präparat HOS-095825
Undesirable effects noted with risperidone formulations
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage d61f331ef416a07980bae2971ae71cd3585ee20051a07464face4d5a0d0ba2d4 · Zeichen 13861–13916 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-124255 · Präparat HOS-095825
Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these
compounds (including both the oral and injectable formulations) are relevant to one another.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 04689c11bdabe405f9fd621ca84cc425697384a84dc895cb5c37998b7850a7ed · Zeichen 13922–14122 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-124256 · Präparat HOS-095825
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 14128–14169 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-124257 · Präparat HOS-095825
Anaphylactic reaction
Rarely, cases of anaphylactic reaction after injection with Xeplion have been reported during
post-marketing experience in patients who have previously tolerated oral risperidone or oral
paliperidone (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 4268883e53a5624cddab48d11e5b4493517714d125353584067d66696a75d1f3 · Zeichen 14175–14427 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-124258 · Präparat HOS-095825
Injection site reactions
The most commonly reported injection site related adverse reaction was pain. The majority of these
reactions were reported to be of mild to moderate severity. Subject evaluations of injection site pain
based on a visual analogue scale tended to lessen in frequency and intensity over time in all Phase 2
and 3 studies with Xeplion. Injections into the deltoid were perceived as slightly more painful than
corresponding gluteal injections. Other injection site reactions were mostly mild in intensity and
included induration (common), pruritus (uncommon) and nodules (rare).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 26879015a976dbd6f7b742e1682743d5cf61121aa2db0d842d5f019c21b5a90c · Zeichen 14433–15055 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-124259 · Präparat HOS-095825
Extrapyramidal symptoms (EPS)
EPS included a pooled analysis of the following terms: parkinsonism (includes salivary
hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia,
hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian
gait, glabellar reflex abnormal, and parkinsonian rest tremor), akathisia (includes akathisia,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 0a647bf07cb13bde63afc876c641cf2e858df95cc1bed537442a5ad550293dae · Zeichen 15061–15491 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 13–14
HOS-124260 · Präparat HOS-095825
13
restlessness, hyperkinesia, and restless leg syndrome), dyskinesia (dyskinesia, muscle twitching,
choreoathetosis, athetosis, and myoclonus), dystonia (includes dystonia, hypertonia, torticollis, muscle
contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial
spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm,
and trismus), and tremor. It should be noted that a broader spectrum of symptoms are included that do
not necessarily have an extrapyramidal origin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 11c7cf168dbdebb0ea6f74d4b6ef9f7253644b5112daaf1903f7b5c91119c3c8 · Zeichen 15558–16110 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124261 · Präparat HOS-095825
Weight gain
In the 13-week study involving the 150 mg initiation dosing, the proportion of subjects with an
abnormal weight increase ≥ 7% showed a dose-related trend, with a 5% incidence rate in the placebo
group compared with rates of 6%, 8% and 13% in the Xeplion 25 mg, 100 mg, and 150 mg groups,
respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 5046be80c46d83ff7f46de876914faec2e6c260ff68744dff455c5776a22284f · Zeichen 16112–16425 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124262 · Präparat HOS-095825
During the 33-week open-label transition/maintenance period of the long-term recurrence prevention
trial, 12% of Xeplion-treated subjects met this criterion (weight gain of ≥ 7% from double-blind phase
to endpoint); the mean (SD) weight change from open-label baseline was + 0.7 (4.79) kg.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage f95adf77dee38b6f01009718daf9cabe73185d6a1bea604b9fe46b1931d07308 · Zeichen 16427–16716 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124263 · Präparat HOS-095825
Hyperprolactinaemia
In clinical trials, median increases in serum prolactin were observed in subjects of both genders who
received Xeplion. Adverse reactions that may suggest increase in prolactin levels (e.g., amenorrhoea,
galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in < 1% of subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 514be57468265e5851e3e1c5e5e28afeb0101bd07381f7c2d5cd05df5e7a7039 · Zeichen 16718–17038 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124264 · Präparat HOS-095825
Class effects
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 9310f6ff6fe3e926d3c05608d3545319594a100ce8fb5e4f653c4e7f9b162727 · Zeichen 17040–17053 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124265 · Präparat HOS-095825
QT prolongation, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia), sudden
unexplained death, cardiac arrest, and Torsade de pointes may occur with antipsychotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 9bdb00a8751a1db6537359db4e3d73d0b337e348336b74273180e73136437820 · Zeichen 17055–17244 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124266 · Präparat HOS-095825
Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein
thrombosis, have been reported with antipsychotic medicinal products (frequency unknown).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 0fd6814702138c1bbf5110a3edd8522e39cec2b2139a85d84a489a5429612194 · Zeichen 17246–17429 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124267 · Präparat HOS-095825
Reporting of suspected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 822da43363cee11e87abeb55cf82453415269315377df150bb5de7dde8dd938f · Zeichen 17431–17471 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 25 mg prolonged release suspension for injection Xeplion 50 mg prolonged release suspension for injection Xeplion 75 mg prolonged release suspension for injection Xeplion 100 mg prolonged release suspension for injection Xeplion 150 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 14
HOS-124268 · Präparat HOS-095825
Reporting suspected adverse reactions after authorisation of the medical product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via the national reporting system listed in Appendix
V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage 0757b417ada575a62062240cb90e5c91a4358a023933b30336cc26c4ab4050e2 · Zeichen 17473–17785 im Abschnitt
Nebenwirkungen · Xeplion
Xeplion 150 mg and Xeplion 100 mg prolonged release suspension for injection · Abschnitt 4.8 · PDF-Seite 30
HOS-124287 · Präparat HOS-095825
Summary of the safety profile
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-03T17:43:00Z · SHA-256 2d38bdc767adb9ede103df61263cd780b613b64f4605afd38720f25f2e234f90 · Passage d55a523b6a19085dba8d780d613791739571d7f51eec366b153cafd8949337ee · Zeichen 0–29 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.